bluebird bio Stock Forecast, Price & News

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 12 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" bluebird bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View analyst ratings for bluebird bio or view top-rated stocks.

Wall Street analysts have given bluebird bio a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but bluebird bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

bluebird bio saw a decline in short interest in the month of May. As of May 28th, there was short interest totaling 5,110,000 shares, a decline of 13.4% from the May 13th total of 5,900,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 3.8 days. Approximately 7.7% of the shares of the company are sold short.
View bluebird bio's Short Interest.

bluebird bio is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for bluebird bio.

bluebird bio, Inc. (NASDAQ:BLUE) announced its earnings results on Tuesday, May, 4th. The biotechnology company reported ($3.07) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($3.02) by $0.05. The biotechnology company had revenue of $12.79 million for the quarter, compared to the consensus estimate of $10.71 million. bluebird bio had a negative net margin of 257.34% and a negative trailing twelve-month return on equity of 43.18%.
View bluebird bio's earnings history.

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BLUE shares have decreased by 46.4% and is now trading at $32.98.
View which stocks have been most impacted by COVID-19.

18 analysts have issued 12 month price objectives for bluebird bio's stock. Their forecasts range from $27.00 to $93.00. On average, they anticipate bluebird bio's share price to reach $60.53 in the next year. This suggests a possible upside of 83.5% from the stock's current price.
View analysts' price targets for bluebird bio or view top-rated stocks among Wall Street analysts.

66 employees have rated bluebird bio CEO Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among bluebird bio's employees.

Some companies that are related to bluebird bio include Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Exelixis (EXEL), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Adaptive Biotechnologies (ADPT), Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX), Beam Therapeutics (BEAM), Abcam (ABCM), Sana Biotechnology (SANA), Kodiak Sciences (KOD), SpringWorks Therapeutics (SWTX), Ablynx (ABLYF) and Iovance Biotherapeutics (IOVA).
View all of BLUE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), (CELG), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.91%), Royal Bank of Canada (5.40%), Armistice Capital LLC (2.91%), Suvretta Capital Management LLC (1.93%), Victory Capital Management Inc. (1.67%) and JPMorgan Chase & Co. (1.62%). Company insiders that own bluebird bio stock include Alison Cecily Finger, Andrew Obenshain, David Davidson, Jeffrey T Walsh, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Philip D Gregory and William D Baird III.
View institutional ownership trends for bluebird bio.

BLUE stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Fiera Capital Corp, Victory Capital Management Inc., Morgan Stanley, Man Group plc, Nuveen Asset Management LLC, New York State Common Retirement Fund, and Price T Rowe Associates Inc. MD. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, Andrew Obenshain, David Davidson, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, and William D Baird III.
View insider buying and selling activity for bluebird bio or view top insider-selling stocks.

BLUE stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Suvretta Capital Management LLC, Sessa Capital IM L.P., Voloridge Investment Management LLC, Deerfield Management Company L.P. Series C, JPMorgan Chase & Co., Royal Bank of Canada, and Ameriprise Financial Inc..
View insider buying and selling activity for bluebird bio or or view top insider-buying stocks.

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLUE stock can currently be purchased for approximately $32.98.

bluebird bio has a market capitalization of $2.22 billion and generates $250.73 million in revenue each year. The biotechnology company earns $-618,700,000.00 in net income (profit) each year or ($9.95) on an earnings per share basis.

bluebird bio employs 1,201 workers across the globe.

The official website for bluebird bio is www.bluebirdbio.com.

bluebird bio is headquartered at 60 BINNEY STREET, CAMBRIDGE MA, 02142.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]